ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BeOne Medicines AG (ONC) is not a strong buy at this moment for a beginner, long-term investor. The stock is currently in a pre-market decline (-1.01%) with mixed technical indicators and no strong proprietary trading signals. While analysts have consistently raised price targets and maintain positive ratings, the company's financial performance shows declining net income and EPS, which could be a concern for long-term growth. Additionally, hedge funds are selling heavily, which may indicate a lack of confidence in the short term. Given the upcoming earnings report, it is prudent to wait for further clarity before making a decision.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 46.849, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 333.994, and resistance is at 356.509. Overall, technical indicators are mixed, with no clear trend.
Analysts have consistently raised price targets, with the latest targets ranging from $394 to $
The company has a strong position in the CLL market and is advancing its solid tumor pipeline.
Upcoming Q4 earnings report and webcast on February 26, 2026, may provide additional insights.
Hedge funds are selling heavily, with a 7307.41% increase in selling activity last quarter.
Financial performance in Q3 2025 showed a significant decline in net income (-202.88% YoY) and EPS (-188.89% YoY), despite revenue growth.
The MACD and pre-market price decline suggest bearish sentiment in the short term.
In Q3 2025, revenue increased by 41.00% YoY to $1.41 billion, but net income dropped by -202.88% YoY to $124.84 million, and EPS fell by -188.89% YoY to $0.08. Gross margin improved slightly to 86.09%, up 3.75% YoY.
Analysts maintain an overwhelmingly positive outlook with multiple firms raising price targets recently (e.g., Barclays to $394, Morgan Stanley to $405, Jefferies to $420). Ratings are predominantly 'Overweight' or 'Buy,' reflecting confidence in the company's long-term growth potential.
